442 Abstracts/ Lung Cancer 11 (1994) 423-444

and 3-year sutvival rates were 60% and 56% for the p&operative chemotherapy patients and 25% and 15% for those who had surgery alone, respectively. Conclusion: In this trial, the treatment strategy using perioperative chemotherapy and surgery was more effective than surgery alone. Implications: This clinical trial strengthens the validity of using perioperative chemotherapy in the management of patients with resectable stage IIIA non-small-cell lung cancer. Further investigation of the perioperative chemotherapy strategy in earlier stage lung cancer is warranted.

Treatment of small cell lung cancer. Recent experience of the EORTC lung cancer cooperative group Van Zandwik N. Department of Chest Oncology, lhe Netherlands Cancer Itutitute, Ple.wnunloan 121, 1066 CX Am.vterdatn. Anticancer Res 199414: B 313-5.

In this paper an overview of the activities since 1982 of the EORTC Lung Cancer Cooperative Group is given. Although the last decade has brought only small improvements, several important questions have been answered. Prognostic factors, optimal duration of chemotherapy, retreatment policies, non-cross resistant combiitions and chemotherapy of brain metastases have been the subject of cooperative effort during the last ten years, allowing batter choices to be made in the treatment of individual patients. Currently the place and timing of radiotherapy and the efficacy of several new drugs are under study. In order to assess reliably the relatively small gains of different treatment options, cooperative groups like the EORTC LCCG will continue to play an important role in the future.

Other treatment modalities Potentiation of long-tennaltured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti- (tumor-associated antigen) biipecific antibody Azuma A, Yagita H, Okumura K, Kudoh S, Niitani H. Departtnent of Internal Medicine, Nippon Medical School, l-l-5 Sendagi. Bunkyo-ku, Tokyo 113. Cancer Immuool Immunother 1994;38:294-8.

Lymphokina+activatedkiller(LAK)cellsexhibitapotent cytotoxicity to malignant cells in vitro. However, a satisfactory effect has not been obtained in many clinical studies except for a few cases. One of the most important reasons why cytolytic activity could not be exhibited in vivo is that LAK cells do not accumulate in the tumor tissue because of a lack of specificity. In the present study, we.show the effect of a bispecific antibody (bsAb) on the accumulation of LAK cells around the small-cell lung carciooms (SCLC!) cell and the subsequent enhancement of LAK cell cytotoxicity against SCLC. When short-term(4days)-cultured LAK cells wereused, 0KT3 x LU246 bsAb, which direct CD3’T-LAK cells to the target cell, induced a similar level of cytotoxicity to that induced by 3G8 x LU246 bsAb, which directs CD16’LAK cells. Longterm (21 days)-cultured LAK cells exhibited a reduced spontaneous cytotoxicity but retained high cytotoxic activity, which could he. directed by 0KT3 x LU246 or 3G8 x LU246 bsAb. The inhibitory effect of LAK cells on tumor cell clonogenicity in soft agar was also enhanced by both bsAb. These. results indicate that application of the therapy with LAK cells and 0KT3 x LU246 bsAb to SCLC patients might be a promising new method of adoptive immunotherapy.

Miscellaneous

Biology of lung cancer Stahel RA. Division of Oncology, Department of Medicine, University Hospital, CH-8091 Zurich. Lung Cancer (Ireland) 1994; 1O:Suppl l:S59-S65.

While the overall survival of patients with lung cancer has remained relatively unchanged over the past decade, there. have been major advances in our understanding of the biology of small cell and non-small cell lung cancer through the study of lung cancer cell lmes. Surface molecules associated with lung cancer have been identified and their molecular structure and function are being elucidated. Growth factors which stimulate the lung cancer cells in an autocrine fashion have been identified. Genetic changes of lung cancer cells have been defined on a chromosomal and a molecular level. This review summarizes many biologic properties of lung cancer cells that have been described in the literature.

Chemotherapy of lung cancer Egger T, Cerny T. Institut fur Medizinische Onkologie. Inselspital, Bern. Ther Umsch 1994;51:267-71.

Lung cancer is still one of the main reasons for death in the western world. Its prevalence follows the pattern of smoking habits. Despite extensive research efforts them is still no breakthrough in systemic therapy of advanced lung cancer. Nevertheless, long-term survival has steadily been increasing during the last decades. This review is focussing on recent progress in treating non-small cell and small cell lung cancer patients.

Epidemiology, screening, and prevention of lung cancer Petersen GM. Depmmtenr OfEpiduniology, JHSHPHOC, Johns Hopkins Sckol of Medicine, 615 North Wolfe Street, Baltimore, MD 21205. Curt Opii Oncol 1994;6:156-61.

With an estimated 170,000 new cases and 149,000 deaths in the United States during 1993, lung cancer is now the leading cause of cancer deaths in both men and women. Tobacco smokiig isan important risk factor, and a large fraction of the risk can be. attributed to it. Other risk factors have been implicated, including environmental tobacco srnoke,occupationalexposureatocarcinogens,andgene.ticsusceptibility. Prevention of lung cancer through early detection and identification of individuals at risk is the goal of many recent studies. This review summarizes the current status of epidemiologic and biomarker research inundemtandingboththeetiologyandprognosticutilityofenvirrnnnental and host factors.

Overview on small cell lung m in the world: IndMrialized countries, third world, Eastern Europe Parkin DM, Sa&ranarayanan R. Unit of Descriptiw Epidemiology, lntemat Ageny Research on Cancer, 150, cows Albert lhomos. 69372 Lyon G&x 08. Anticancer Res 1994; 14: B 277-82.

Lung cancer cases were abstracted from cancer registries in 20 countries to study the distribution of small cell lung cancer around 1985. The international patterns of small cell lung cancer resemble those of squamous cell tumors, and of lung cancer as a whole. Cigarette smoking andoccupationalri~factorsaremorestronglyaasociatedwithsquamous and small cell lung cancers than with adenocaminoma. Inspection of sex differences and time trends in incidence show some differences which may relate. to a higher risk for small cell lung cancer in female smokers than in males, and a less rapid decline in risk on smoking cessation.

small cell lung cnncer treatment Schuller MP, Lebeau B. Service de Pneutnologie, Hopital Saint- Antoine, 184 Rue du Fbg Saint-Antoine, 75571 Paris Cedex 12. Med Hyg 1994;52:797-9.